NZ595364A - TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION - Google Patents
TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTIONInfo
- Publication number
- NZ595364A NZ595364A NZ595364A NZ59536410A NZ595364A NZ 595364 A NZ595364 A NZ 595364A NZ 595364 A NZ595364 A NZ 595364A NZ 59536410 A NZ59536410 A NZ 59536410A NZ 595364 A NZ595364 A NZ 595364A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- cell dysfunction
- pancreatic beta
- tissue kallikrein
- kallikrein
- Prior art date
Links
- 101710176219 Kallikrein-1 Proteins 0.000 title 1
- 102000057032 Tissue Kallikreins Human genes 0.000 title 1
- 230000004053 pancreatic β cell dysfunction Effects 0.000 title 1
- 230000004064 dysfunction Effects 0.000 abstract 2
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 abstract 1
- 102100038297 Kallikrein-1 Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16317309P | 2009-03-25 | 2009-03-25 | |
| PCT/CA2010/000413 WO2010108262A1 (en) | 2009-03-25 | 2010-03-25 | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595364A true NZ595364A (en) | 2013-09-27 |
Family
ID=42780097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595364A NZ595364A (en) | 2009-03-25 | 2010-03-25 | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120070425A1 (enExample) |
| EP (1) | EP2411042A4 (enExample) |
| JP (1) | JP2012521366A (enExample) |
| CN (1) | CN102438648A (enExample) |
| AU (1) | AU2010228068A1 (enExample) |
| CA (1) | CA2756801A1 (enExample) |
| NZ (1) | NZ595364A (enExample) |
| WO (1) | WO2010108262A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008280782B2 (en) | 2007-07-20 | 2014-01-23 | Diamedica Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| CN103889435A (zh) * | 2011-06-17 | 2014-06-25 | 约翰斯·霍普金斯大学 | 用于增加胰岛素敏感性和治疗糖尿病的方法 |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
| CN109498815B (zh) | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
| KR20190122706A (ko) | 2017-03-09 | 2019-10-30 | 다이어메디카 인코포레이티드 | 조직 칼리크레인 1의 투약 형태 |
| CN112481268B (zh) * | 2021-01-25 | 2024-01-30 | 河南大学 | 一种棉花启动子PGhPGF及其重组载体和应用 |
| CN116135973A (zh) * | 2021-11-16 | 2023-05-19 | 江苏众红生物工程创药研究院有限公司 | 低糖基化修饰的激肽原酶及其聚乙二醇修饰物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| KR20010052371A (ko) * | 1998-05-22 | 2001-06-25 | 엔트리메드 인코포레이티드 | 세린 프로테아제를 이용한 내피 세포 증식 억제 및안기오게네시스 조절을 위한 조성물 및 방법 |
| CN1228447C (zh) * | 2001-02-20 | 2005-11-23 | 深圳市人民医院 | 一种含有人胰腺组织激肽释放酶成熟蛋白基因的重组表达载体 |
| CN100338212C (zh) * | 2003-01-29 | 2007-09-19 | 中国科学院大连化学物理研究所 | 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用 |
| CN101094869A (zh) * | 2004-08-03 | 2007-12-26 | 戴埃克斯有限公司 | Hk1结合蛋白 |
| JP2008515774A (ja) * | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US20100008899A1 (en) * | 2006-07-26 | 2010-01-14 | Diamedica, Inc. | Methods of diagnosis and treatment for metabolic disorders |
| JP5322935B2 (ja) * | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| CN101134953B (zh) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | 重组人胰激肽原酶 |
| CN101255438B (zh) * | 2008-04-11 | 2012-01-25 | 深圳大学 | 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法 |
-
2010
- 2010-03-25 NZ NZ595364A patent/NZ595364A/xx not_active IP Right Cessation
- 2010-03-25 WO PCT/CA2010/000413 patent/WO2010108262A1/en not_active Ceased
- 2010-03-25 JP JP2012501089A patent/JP2012521366A/ja active Pending
- 2010-03-25 CN CN2010800181825A patent/CN102438648A/zh active Pending
- 2010-03-25 EP EP10755352A patent/EP2411042A4/en not_active Ceased
- 2010-03-25 AU AU2010228068A patent/AU2010228068A1/en not_active Abandoned
- 2010-03-25 CA CA2756801A patent/CA2756801A1/en not_active Abandoned
-
2011
- 2011-09-23 US US13/241,882 patent/US20120070425A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012521366A (ja) | 2012-09-13 |
| US20120070425A1 (en) | 2012-03-22 |
| WO2010108262A1 (en) | 2010-09-30 |
| EP2411042A1 (en) | 2012-02-01 |
| CA2756801A1 (en) | 2010-09-30 |
| AU2010228068A1 (en) | 2011-10-20 |
| CN102438648A (zh) | 2012-05-02 |
| EP2411042A4 (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595364A (en) | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION | |
| IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| NZ602925A (en) | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy | |
| NZ603319A (en) | Diabetes therapy | |
| IL185808A0 (en) | Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments | |
| MY151048A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| IN2012DN02805A (enExample) | ||
| IN2012DN01233A (enExample) | ||
| PH12013502262A1 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors | |
| IN2012DN02471A (enExample) | ||
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| MX2009007247A (es) | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. | |
| UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| PH12013500361A1 (en) | Preventive or therapeutic agent for fibrosis | |
| IL198202A0 (en) | Peptide-cytotoxic conjugates | |
| TW200833343A (en) | Novel therapeutic utilization for the treatment of leukaemias | |
| WO2011056850A3 (en) | Linaclotide for the treatment of chronic constipation | |
| MX2010004315A (es) | Compuestos para inhibir la actividad de quinesina ksp. | |
| MX2008001506A (es) | Uso de sales de triotropio en el tratamiento de asma severa persistente. | |
| MX2009008040A (es) | Uso de arcillas para tratar la enfermedad celiaca. | |
| MY146362A (en) | Use of tiotropium salts in the treatment of moderate persistent asthma | |
| AR048460A1 (es) | Tratamiento de la funcion respiratoria alterada con gaboxadol | |
| MX2009002091A (es) | Metodos para reducir las concentraciones de glucosa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2017 BY COMPUTER PACKAGES INC Effective date: 20140328 |
|
| LAPS | Patent lapsed |